MedTap: Why mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction?

MedTap: Why mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction?


MedTap: Why mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction?

null


Content

5.84 -> Mineralocorticoid receptor antagonists  (known as MRAs) are often prescribed in patients  
11.84 -> with heart failure with reduced ejection fraction.  These medications are spironolactone and eplerenone.
21.84 -> They're started in patients who  still have heart failure symptoms  
25.6 -> despite being on a beta blocker  and an ACE-I inhibitor or equivalent.
32.08 -> MRAs work with your kidneys to prevent the  build-up of salt and water in your blood.  
38.32 -> This allows your heart to pump blood around your body more easily. You may not always be able to tell
46 -> that your MRA is working but you should hopefully  start to notice an improvement in your symptoms  
51.36 -> after a few weeks. MRAs are key medications. They help you to reduce the need to be hospitalised,  
60.72 -> they make you feel better  and they make you live longer.  
65.04 -> MRAs are usually continued long  term to help support your heart.

Source: https://www.youtube.com/watch?v=LwoqZWQKDHI